What is Excellos?
Excellos operates at the intersection of clinical research and industrial-scale manufacturing, leveraging its deep roots with the San Diego Blood Bank to provide high-quality cGMP cellular products. By offering comprehensive process development and manufacturing expertise, the firm serves as a critical partner for scientists and clinicians navigating the rigorous demands of regenerative medicine. Its market position is defined by a commitment to bridging the gap between laboratory-scale innovation and commercial-grade production, ensuring that next-generation therapies reach patients with greater efficiency and reliability.
How much funding has Excellos raised?
Excellos has raised a total of $15M across 1 funding round:
Other Financing Round
$15M
Other Financing Round (2022): $15M with participation from Telegraph Hill Partners
Key Investors in Excellos
Telegraph Hill Partners
Telegraph Hill Partners is a San Francisco-based private equity firm that specializes in providing growth capital to commercial-stage companies within the life science, medical technology, and healthcare sectors.
What's next for Excellos?
Looking ahead, the company is poised to leverage this major enterprise-level funding to expand its manufacturing footprint and enhance its service offerings. The strategic deployment of these resources will likely focus on optimizing cGMP workflows and increasing capacity to meet the surging demand for high-purity cellular materials. As the cell and gene therapy landscape continues to mature, Excellos is strategically aligned to become a foundational pillar in the global clinical supply chain, facilitating the transition of breakthrough research into viable, life-saving medical treatments.
See full Excellos company page
